Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation
- PMID: 3539172
- DOI: 10.1111/j.1365-2141.1986.tb02203.x
Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation
Abstract
We have developed a rapid and simple procedure for the elimination of mature T-cells from the donor marrow using a single incubation with the monoclonal antibody Campath-1 and donor complement. This resulted in a reduction of T-cell contamination to a mean of 1%. This regimen reduced the incidence of acute graft-versus-host disease significantly in 21 consecutive bone marrow grafts in 18 patients with leukaemia and non-Hodgkin's lymphoma. Purging was responsible for an increased incidence of graft rejection in HLA-identical transplants (13%).
Similar articles
-
Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms.Prog Clin Biol Res. 1990;333:139-51; discussion 152-4. Prog Clin Biol Res. 1990. PMID: 2308978
-
Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.Bone Marrow Transplant. 1994 May;13(5):597-611. Bone Marrow Transplant. 1994. PMID: 8054913
-
Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.J Clin Oncol. 1992 Jul;10(7):1191-200. doi: 10.1200/JCO.1992.10.7.1191. J Clin Oncol. 1992. PMID: 1607923
-
T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation?BioDrugs. 2003;17(3):147-54. doi: 10.2165/00063030-200317030-00001. BioDrugs. 2003. PMID: 12749751 Review.
-
'Purging' of bone marrow and immunosuppression.Br Med Bull. 1984 Jul;40(3):247-53. doi: 10.1093/oxfordjournals.bmb.a071985. Br Med Bull. 1984. PMID: 6380636 Review. No abstract available.
Cited by
-
Advances in Immunotherapy for the Treatment of Cutaneous T-Cell Lymphoma.Cancer Manag Res. 2023 Sep 6;15:989-998. doi: 10.2147/CMAR.S330908. eCollection 2023. Cancer Manag Res. 2023. PMID: 37700809 Free PMC article. Review.
-
Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL).Biologics. 2008 Mar;2(1):41-52. doi: 10.2147/btt.s1397. Biologics. 2008. PMID: 19707426 Free PMC article.
-
The Graft-Versus-Leukemia Effect in AML.Front Oncol. 2019 Nov 19;9:1217. doi: 10.3389/fonc.2019.01217. eCollection 2019. Front Oncol. 2019. PMID: 31803612 Free PMC article. Review.
-
The Anti-Human P2X7 Monoclonal Antibody (Clone L4) Can Mediate Complement-Dependent Cytotoxicity of Human Leukocytes.Eur J Immunol. 2025 Jan;55(1):e202451196. doi: 10.1002/eji.202451196. Eur J Immunol. 2025. PMID: 39853757 Free PMC article.
-
Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy.Immunol Rev. 2014 Mar;258(1):167-82. doi: 10.1111/imr.12155. Immunol Rev. 2014. PMID: 24517433 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials